Liver cancer is uncommon in the United States, but it is common worldwide due to risk factors such as chronic hepatitis B and C infections and exposure to aflatoxin (toxins produced by a certain ...
Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study ...
The (AGA) has unveiled an updated clinical practice guideline in Gastroenterology addressing the prevention and management of hepatitis B virus reactivation (HBVr) in patients on immunosuppressive ...
Estimates suggest that about 240 million people around the world have chronic hepatitis B. Up to 1.89 million people in the ... Romanò L, Paladini S, Galli C, Raimondo G, Pollicino T, Zanetti AR.
The global hepatitis diagnostic test market is poised for significant growth, with market value projected to increase from USD 3621.5 million in 2024 to USD 6118.4 million by 2033, reflecting a steady ...
GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen ... cure could be around the same size as for hepatitis C virus, which peaked at around $10 billion a year, but was ...
Brii said it agreed to purchase the assets from VBI Vaccines Inc. and its creditors for $18 million. The deal gives Brii full access to the remaining IP, patents and materials related to BRII-179, an ...